Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$718 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
5.2
Industry P/E
--
EV/EBITDA
-7.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.2
Face value
--
Shares outstanding
57,084,838
CFO
$-334.55 Mln
EBITDA
$-189.27 Mln
Net Profit
$-360.34 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Astria Therapeutics (ATXS)
| -4.7 | -3.4 | 4.7 | 60.2 | -4.3 | -4.4 | -27.9 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Astria Therapeutics (ATXS)
| 46.4 | 16.3 | -48.4 | 176.3 | -58.0 | -63.8 | 35.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Astria Therapeutics (ATXS)
|
12.5 | 718.1 | 0.7 | -124.0 | -14,499.0 | -47.5 | -- | 5.2 |
| 61.0 | 8,546.2 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.1 | 15.0 | |
| 229.3 | 14,074.4 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 8,218.7 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 43.9 | 11,764.8 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 93.8 | 12,307.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 60.9 | |
| 546.9 | 12,545.6 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 498.3 | 14,143.5 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.7 | 30.2 | |
| 105.4 | 8,288.6 | 0.0 | -425.4 | -- | -36.7 | -- | 6.7 | |
| 310.4 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal... antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc. Read more
Co-Founder, CEO, President & Director
Ms. Jill C. Milne Ph.D.
Co-Founder, CEO, President & Director
Ms. Jill C. Milne Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Astria Therapeutics Inc (ATXS) is $12.48 (NASDAQ) as of 16-Jan-2026 12:34 EDT. Astria Therapeutics Inc (ATXS) has given a return of -4.3% in the last 3 years.
Since, TTM earnings of Astria Therapeutics Inc (ATXS) is negative, P/E ratio is not available.
The P/B ratio of Astria Therapeutics Inc (ATXS) is 5.21 times as on 20-Mar-2026, a 31 premium to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-5.31
|
1.57
|
|
2023
|
-3.16
|
0.95
|
|
2022
|
-4.45
|
1.01
|
|
2021
|
-0.25
|
0.40
|
|
2020
|
-0.17
|
0.16
|
The 52-week high and low of Astria Therapeutics Inc (ATXS) are Rs 5,784.30 and Rs 3.56 as of 05-Apr-2026.
Astria Therapeutics Inc (ATXS) has a market capitalisation of $ 718 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Astria Therapeutics Inc (ATXS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.33
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.